Dementia in Parkinson's disease

Current Opinion in Neurology

Volumn 21, Issue 6, 2008, Pages 676-682

  Aarsland, Dag ^a,c,d   Beyer, Mona K ^b   Kurz, Martin W ^a  

^a Norwegian Centre for Movement Disorders   (Norway)

^b STAVANGER UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

synuclein; Dementia; Genetics; Mild cognitive impairment; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; AMANTADINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; MEMANTINE; PROTEIN; RIVASTIGMINE;

ALZHEIMER DISEASE; BRAIN REGION; CEREBROSPINAL FLUID ANALYSIS; CLINICAL GENETICS; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; ELECTROPHYSIOLOGY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; IN VIVO STUDY; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PROTEIN AGGREGATION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

DEMENTIA; DIAGNOSTIC IMAGING; ELECTROPHYSIOLOGY; HUMANS; PARKINSON DISEASE;

EID: 56749136301     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3283168df0     Document Type: Review

References (81)

1. Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007; 68:812-819. This is a consensus report from a DLB/PDD Working Group, established to follow up recommendations made in the third report of the DLB Consortium on current status and future research recommendations on the interface between DLB and PDD.
2. Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23:837-844. This is the longest prospective study of a cohort with early Parkinson's disease, which shows that nearly all patients who survived for 20 years after disease onset will develop dementia.
3. Buter TC, van den Hout A, Matthews FE, et al. Dementia and survival in Parkinson disease: a 12-year population study. Neurology 2008; 70:1017-1022. This is a 12-year prospective study based on a prevalence sample. In addition to demonstrating the very high cumulative risk for dementia, Markov analysis was used to estimate the risk for dementia for an individual patient.
4. Aarsland D, Kvaloy JT, Andersen K, et al. The effect of age of onset of PD on risk of dementia. J Neurol 2007; 254:38-45.
5. Alves G, Larsen JP, Emre M, et al. Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord 2006; 21:1123-1130.
6. Williams-Gray CH, Foltynie T, Brayne CE, et al. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007; 130 (Pt 7):1787-1798. This is the first longitudinal study of cognitive functioning in an incident Parkinson's disease cohort. Frontostriatal and posterior cortical cognitive deficits were shown, and motor and nonmotor patterns associated with dementia were found.
7. Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005; 65:1239-1245.
8. Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord 2006; 21:1343-1349.
9. Beyer MK, Janvin CC, Larsen JP, Aarsland D. A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry 2007; 78:254-259.
10. Meyer JS, Huang J, Chowdhury MH. MRI confirms mild cognitive impairments prodromal for Alzheimer's, vascular and Parkinson-Lewy body dementias. J Neurol Sci 2007; 257 (1-2):97-104.
11. Huang C, Mattis P, Perrine K, et al. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 2008; 70 (16 Pt 2):1470-1477. This study demonstrates for the first time a metabolic basis for MCl-Parkinson's disease, involving decreased parietal and prefrontal metabolism.
12. Klein C, Schlossmacher MG. Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder. Neurology 2007; 69:2093-2104.
13. Kurz MW, Larsen JP, Kvaloy JT, Aarsland D. Associations between family history of Parkinson's disease and dementia and risk of dementia in Parkinson's disease: a community-based, longitudinal study. Mov Disord 2006; 21:2170-2174.
14. Ahn TB, Kim SY, Kim JY, et al. alpha-Synuclein gene duplication is present in sporadic Parkinson disease. Neurology 2008; 70:43-49.
15. Farrer M, Kachergus J, Forno L, et al. Comparison of kindreds with Parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 2004; 55:174-179.
16. Ross OA, Wu YR, Lee MC, et al. Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann Neurol 2008; 64:88-92. This study reports on five families harbouring duplication or triplication of SNCA. In addition to showing a dose-relationship with clinical severity, a mechanistic hypothesis for the multiplication is provided.
17. Tsuang DW, Wilson RK, Lopez OL, et al. Genetic association between the APOE*4 allele and Lewy bodies in Alzheimer disease. Neurology 2005; 64:509-513.
18. Wakabayashi K, Kakita A, Hayashi S, et al. Apolipoprotein E epsilon4 allele and progression of cortical Lewy body pathology in Parkinson's disease. Acta Neuropathol 1998; 95:450-454.
19. Ghebremedhin E, Del Tredici K, Vuksic M, et al. Relationship of apolipoprotein E and age at onset to Parkinson disease neuropathology. J Neuropathol Exp Neurol 2006; 65:116-123.
20. Huang X, Chen P, Kaufer DI, et al. Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. Arch Neurol 2006; 63:189-193.
21. Jasinska-Myga B, Opala G, Goetz CG, et al. Apolipoprotein E gene polymorphism, total plasma cholesterol level, and Parkinson disease dementia. Arch Neurol 2007; 64:261-265. This study is based on a large cohort and excluded patients with vascular dementia, DLB, or cortical dementia. E4 allele frequencies were similar in PDD and nondemented Parkinson's disease.
22. Scott WK, Nance MA, Watts RL, et al. Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA 2001; 286:2239-2244.
23. Goris A, Williams-Gray CH, Clark GR, et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol 2007; 62:145-153. This longitudinal study of a large cohort of patients with Parkinson's disease suggests a role for the tau gene for dementia in Parkinson's disease. Furthermore, the findings indicate an interaction between the SNCA and tau genes.
24. Haugarvoll K, Rademakers R, Kachergus JM, et al. Lrrk2 R1441C Parkinsonism is clinically similar to sporadic Parkinson disease. Neurology 2008; 70 (16 Pt 2):1456-1460. This study reports on 33 affected LRRK2 p.R1441C carriers. The phenotype, including proportion with MCl and dementia, seems to be similar to idiopathic Parkinson's disease.
25. Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008; 7:583-590. This study presents genotype-phenotype correlations in 1045 patients with mutations in LRRK2 and compares this to 543 patients with pathologically confirmed Parkinson's disease. Convincing evidence of more benign course in carriers of the common LRRK2 G2019Ser mutation is shown, including a reduced rate of cognitive decline.
26. Lucking CB, Durr A, Bonifati V, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 2000; 342:1560-1567.
27. Schlossmacher MG, Frosch MP, Gai WP, et al. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol 2002; 160:1655-1667.
28. Pramstaller PP, Schlossmacher MG, Jacques TS, et al. Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers. Ann Neurol 2005; 58:411-422.
29. Braak H, Ghebremedhin E, Rub U, et al. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318:121-134.
30. Braak H, Rub U, Del Tredici K. Cognitive decline correlates with neuropathological stage in Parkinson's disease. J Neurol Sci 2006; 248 (1-2):255-258.
31. Ballard C, Ziabreva I, Perry R, et al. Differences in neuropathology characteristics across the Lewy body dementia spectrum. Neurology 2006; 67:1931-1934.
32. Kramer ML, Schulz-Schaeffer WJ. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 2007; 27:1405-1410. This study employed novel techniques such as paraffin-embedded tissue and protein aggregate filtration and demonstrated that the majority of α-synuclein disorders are in the form of small aggregates located at presynaptic terminals.
33. Halliday G, Hely M, Reid W, Morris J. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol 2008; 115:409-415. This is the largest clinicopathologic study of a prospectively followed Parkinson's disease cohort. Three different neuropathological groups were identified with different clinical courses.
34. Lashley T, Holton JL, Gray E, et al. Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients. Acta Neuropathol 2008; 115:417-425.
35. McNaught KS, Olanow CW, Halliwell B, et al. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev 2001; 2:589-594.
36. Macinnes N, Iravani MM, Perry E, et al. Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systems. J Neural Transm 2008; 115:869-878. This is the first study demonstrating proteasome system dysfunction also in cortical Lewy body disease. In addition, an animal model of cortical Lewy body disease was convincingly shown.
37. Leverenz JB, Umar I, Wang Q, et al. Proteomic identification of novel proteins in cortical Lewy bodies. Brain Pathol (Zurich, Switzerland) 2007; 17:139-145. This is the first study employing proteomics to study the protein content of Lewy bodies postmortem. Among the proteasomal abnormalities observed, candidates included those involved in UPS protein degradation, folding, and oxidative stress, supporting hypotheses involving these systems in the pathology of cortical Lewy body disease.
38. Francis PT, Perry EK. Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies. Mov Disord 2007; 22 (S 17):S351-S357. This is a comprehensive and up-to-date review of neurochemical changes associated with dementia in Parkinson's disease.
39. Burton FJ, McKeith IG, Burn DJ, et al. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 2004; 127 (R 4):791-800.
40. Burton EJ, McKeith IG, Burn DJ, O'Brien JT. Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging. Mov Disord 2005; 20:1571-1576.
41. Almeida OP, Burton EJ, McKeith I, et al. MRI study of caudate nucleus volume in Parkinson's disease with and without dementia with Lewy bodies and Alzheimer's disease. Dement Geriatr Cogn Disord 2003; 16:57-63.
42. Junque C, Ramirez-Ruiz B, Tolosa E, et al. Amygdalar and hippocampal MRI volumetric reductions in Parkinson's disease with dementia. Mov Disord 2005; 20:540-544.
43. Bouchard TP, Malykhin N, Martin WR, et al. Age and dementia-associated atrophy predominates in the hippocampal head and amygdala in Parkinson's disease. Neurobiol Aging 2008; 29:1027-1039.
44. Jokinen P, Bruck A, Aalto S, et al. Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord 2008 [Epub ahead of print].
45. Apostolova LG, Thompson PM. Brain mapping as a tool to study neurodegeneration. Neurotherapeutics 2007; 4:387-400.
46. Matsui H, Nishinaka K, Oda M, et al. Dementia in Parkinson's disease: diffusion tensor imaging. Acta Neurol Scand 2007; 116:177-181. This is the first study using diffusion tension imaging in PDD. The results demonstrate the usefulness of the technique, as well as the relevance of posterior cingulate bundles for dementia in Parkinson's disease.
47. Camicioli RM, Korzan JR, Foster SL, et al. Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia. Neurosci Lett 2004; 354:177-180.
48. Griffith HR, den Hollander JA, Okonkwo OC, et al. Brain N-acetylaspartate is reduced in Parkinson disease with dementia. Alzheimer Dis Assoc Disord 2008; 22:54-60.
49. Stebbins GT, Goetz CG, Carrillo MC, et al. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology 2004; 63:1409-1416.
50. Huang C, Mattis P, Tang C, et al. Metabolic brain networks associated with cognitive function in Parkinson's disease. Neurolmage 2007; 34:714-723. Several reports from this group using fMRI to explore activation patterns associated with cognition in Parkinson's disease. They found a specific network associated with cognition in Parkinson's disease, which is associated with MCl and changes over time.
51. Huang C, Tang C, Feigin A, et al. Changes in network activity with the progression of Parkinson's disease. Brain 2007; 130 (Pt 7):1834-1846.
52. Trojanowski JQ, Lee VM. Parkinson's disease and related alpha-synucleinopathies are brain amyloidoses. Ann N Y Acad Sci 2003; 991:107-110.
53. Maetzler W, Reimold M, Liepelt I, et al. [11C]PIB binding in Parkinson's disease dementia. NeuroImage 2008; 39:1027-1033. This is the first study exploring PIB-PET in PDD. In addition, using autopsy tissue, the authors showed for the first time specific binding of PIB to amyloid plaques as well as Lewy bodies.
54. Ye L, Velasco A, Fraser G, et al. In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J Neurochem 2008; 105:1428-1437.
55. Bonanni L, Thomas A, Tiraboschi P, et al. EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. Brain 2008; 131 (Pt 3):690-705. This is the most comprehensive study of EEG in PDD and DLB, using novel technology, including frequency variability. Characteristic changes were found in DLB and PDD, which distinguished DLB and PDD from Alzheimer's disease with high accuracy.
56. Bronnick KS, Nordby H, Larsen JP, Aarsland D. Disturbance of automatic auditory change detection in dementia associated with Parkinson's disease: a mismatch negativity study. Neurobiol Aging 2008 [Epub ahead of print]. This is the first study to use mismatch negativity paradigm as a measure of automatic attention in PDD. Characteristic changes were found in PDD, which were more pronounced than those observed in DLB.
57. Mollenhauer B, Trenkwalder C, von Ahsen N, et al. Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Cogn Disord 2006; 22:200-208.
58. Parnetti L, Tiraboschi P, Lanari A, et al. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry 2008 [Epub ahead of print].
59. El-Agnaf OM, Salem SA, Paleologou KE, et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 2006; 20:419-425.
60. Tokuda T, Salem SA, Allsop D, et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 2006; 349:162-166.
61. Mollenhauer B, Cullen V, Kahn I, et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 2008 [Epub ahead of print].
62. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22:1689-1707; quiz 837. This is the report from a Task Force, organized by the Movement Disorder Study for the development of clinical diagnostic criteria for PDD. In addition, the paper contains a comprehensive and systematic review of the literature.
63. Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the Movement Disorder Society task force. Mov Disord 2007; 22:2314-2324. This is another report from the MDS Task Force for PDD, providing diagnostic procedures for PDD, both for clinical practice and research.
64. Galvin JE, Pollack J, Morris JC. Clinical phenotype of Parkinson disease dementia. Neurology 2006; 67:1605-1611.
65. Bronnick K, Emre M, Lane R, et al. Profile of cognitive impairment in dementia associated with Parkinson's disease compared with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2007; 78:1064-1068. This is by far the largest cohort to explore the patterns of cognitive impairment in Alzheimer's disease and PDD, demonstrating attentional impairment as a key feature of PDD.
66. Janvin CC, Larsen JP, Salmon DP, et al. Cognitive profiles of individual patients with Parkinson's disease and dementia: comparison with dementia with Lewy bodies and Alzheimer's disease. Mov Disord 2006; 21:337-342.
67. Aarsland D, Bronnick K, Ehrt U, et al. Neuropsychiatrie symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated caregiver stress. J Neurol Neurosurg Psychiatry 2007; 78:36-42. This study uses cluster analysis to identify a characteristic neuropsychiatric syndrome profile in a large cohort of patients with PDD.
68. Kulisevsky J, Pagonbarraga J, Pascual-Sedano B, et al., Trapecio Group Study. Prevalence and correlates of neuropsychiatrie symptoms in Parkinson's disease without dementia. Mov Disord 2008 [Epub ahead of print]. This is the largest study to date, reporting the neuropsychiatric symptoms and cluster analysis of 1351 patients with Parkinson's disease. Eighty-seven per cent of the subjects reported at least one psychiatric symptom, such as depression (70%), anxiety (69%), apathy (48%), and irritability (47%).
69. Muslimovic D, Schmand B, Speelman JD, de Haan RJ. Course of cognitive decline in Parkinson's disease: a meta-analysis. J Int Neuropsychol Soc 2007; 13:920-932. This is a meta-analysis of 25 longitudinal studies to examine cognitive decline in patients with nondemented Parkinson's disease, calculating effect sizes for change in eight cognitive domains.
70. Aarsland D, Andersen K, Larsen JP, et al. The rate of cognitive decline in Parkinson disease. Arch Neurol 2004; 81:1906-1911.
71. Muslimovic D, Post B, Speelman JD, et al. Determinants of disability and quality of life in mild to moderate Parkinson disease. Neurology 2008; 70:2241-2247.
72. Bronnick K, Ehrt U, Emre M, et al. Attentional deficits affect activities of dairy living in dementia associated with Parkinson's disease. J Neurol Neurosurg Psychiatry 2008; 77:1138-1142.
73. Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006; 21:1899-1907.
74. Perry EK, Kilford L, Lees AJ, et al. Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol 2003; 54:235-238.
75. Inzelberg R, Bonuccelli U, Schechtman E, et al. Association between amantadine and the onset of dementia in Parkinson's disease. Mov Disord 2006; 21:1375-1379.
76. Merello M, Nouzeilles MI, Cammarota A, Leiguarda R. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. Clin Neuropharmacol 1999; 22:273-276.
77. Puzin MN, Krivonos OV, Kozhevnikova Zh V. Akatinol memantine in the therapy of cognitive disorders in Parkinson's disease. Zh Nevrol Psikhiatr Im S S Korsakova 2007; 107:26-29.
78. Ridha BH, Josephs KA, Rossor MN. Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. Neurology 2005; 65:481-482.
79. Parsons TD, Rogers SA, Braaten AJ, et al. Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta-analysis. Lancet Neurol 2006; 5:578-588.
80. Woods SP, Rippeth JD, Conover E, et al. Statistical power of studies examining the cognitive effects of subthalamic nucleus deep brain stimulation in Parkinson's disease. Clin Neuropsychol 2006; 20:27-38.
81. Witt K, Daniels C, Reiff J, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. Lancet Neurol 2008; 7:605-614. This is one of the first large randomized multicentre studies comparing the cognitive effects of deep brain stimulation of the subthalamic nucleus with that of best medical treatment. Although overall cognition did not differ, DBS was associated with a greater decline in selected frontal cognitive functions.